Free Trial
→ Elon just did WHAT!? (From Brownstone Research) (Ad) Buy CVAC Stock  Free CVAC Stock Alerts

CureVac (CVAC) Financials

CureVac logo
$4.09 -0.07 (-1.68%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$4.15 +0.06 (+1.56%)
As of 05/23/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for CureVac

Annual Income Statements for CureVac

This table shows CureVac's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 168 -288 -266 -466 -158 -112 -82
Consolidated Net Income / (Loss)		 168 -288 -266 -466 -158 -112 -82
Net Income / (Loss) Continuing Operations		 168 -288 -266 -466 -158 -112 -82
Total Pre-Tax Income 		198 -288 -267 -467 -159 -112 -81
Total Operating Income		 198 -288 -267 -467 -159 -112 -83
Total Gross Profit		 433 -54 -85 572 47 -6.91 -5.58
Total Revenue		 578 88 117 855 92 27 15
Operating Revenue		 578 88 117 855 92 27 -
Total Cost of Revenue		 145 142 202 283 45 34 20
Operating Cost of Revenue		 145 142 202 283 45 34 20
Total Operating Expenses		 235 234 181 1,039 205 105 78
Selling, General & Admin Expense		 77 106 114 116 66 57 29
Research & Development Expense		 158 128 67 923 139 49 48
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.00 0.00 1.94
Income Tax Expense		 30 0.22 -0.13 -0.89 -0.89 -0.28 0.13
Basic Earnings per Share		 $0.75 ($1.18) ($1.32) ($2.21) ($0.98) ($1.03) -
Weighted Average Basic Shares Outstanding		 224.34M 223.99M 194.95M - 187.12M - -
Diluted Earnings per Share		 $0.75 ($1.18) ($1.32) ($2.21) ($0.98) ($1.03) -
Weighted Average Diluted Shares Outstanding		 224.34M 223.99M 194.95M - 187.12M - -
Weighted Average Basic & Diluted Shares Outstanding		 224.34M 223.99M 194.95M - 187.12M - -

Quarterly Income Statements for CureVac

No quarterly income statements for CureVac are available.

Annual Cash Flow Statements for CureVac

This table details how cash moves in and out of CureVac's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 81 -102 -339 -584 1,584 49 -90
Net Cash From Operating Activities		 105 -296 -306 -830 638 -3.74 -85
Net Cash From Continuing Operating Activities		 86 -323 -336 -932 658 -3.74 -78
Net Income / (Loss) Continuing Operations		 198 -288 -267 -467 -159 0.00 -81
Consolidated Net Income / (Loss)		 198 -288 -267 -467 -159 - -81
Non-Cash Adjustments To Reconcile Net Income		 27 51 115 -398 48 -0.65 -6.74
Changes in Operating Assets and Liabilities, net		 -139 -113 -210 -85 756 -11 5.36
Net Cash From Investing Activities		 -19 -61 -100 -145 -55 53 -4.88
Net Cash From Continuing Investing Activities		 -19 -61 -100 -145 -55 53 -17
Purchase of Property, Plant & Equipment		 -19 -61 -100 -145 -58 - -17
Acquisitions		 0.00 0.00 -0.30 0.00 0.00 - -
Net Cash From Financing Activities		 -5.29 255 68 390 1,002 0.00 -0.13
Net Cash From Continuing Financing Activities		 -5.29 255 -4.52 425 971 0.00 -0.13
Repayment of Debt		 -5.29 -5.74 -4.52 -32 -119 - -0.13
Issuance of Common Equity		 0.00 261 0.00 457 1,060 0.00 0.00

Quarterly Cash Flow Statements for CureVac

No quarterly cash flow statements for CureVac are available.

Annual Balance Sheets for CureVac

This table presents CureVac's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 831 872 921 1,311 1,846 147
Total Current Assets		 545 529 625 1,064 1,698 64
Cash & Equivalents		 499 445 530 918 1,616 34
Accounts Receivable		 15 16 6.73 21 1.24 18
Inventories, net		 0.56 27 37 64 18 6.95
Prepaid Expenses		 17 26 43 56 59 1.89
Current Deferred & Refundable Income Taxes		 6.00 5.75 0.30 - - -
Other Current Assets		 2.86 3.05 - - 0.99 -
Other Current Nonoperating Assets		 3.75 2.94 4.80 5.26 3.20 1.64
Plant, Property, & Equipment, net		 212 262 212 190 81 54
Plant, Property & Equipment, gross		 212 262 212 190 81 54
Total Noncurrent Assets		 74 80 84 57 67 28
Intangible Assets		 26 31 34 15 17 6.39
Noncurrent Deferred & Refundable Income Taxes		 5.27 - 1.39 3.24 0.54 0.00
Other Noncurrent Operating Assets		 43 48 49 38 49 22
Total Liabilities & Shareholders' Equity		 831 872 921 1,311 1,846 147
Total Liabilities		 110 300 350 532 977 195
Total Current Liabilities		 75 206 167 405 302 32
Accounts Payable		 18 53 79 145 26 7.27
Current Deferred & Payable Income Tax Liabilities		 19 - 0.65 0.84 0.48 0.12
Other Current Liabilities		 38 152 88 260 276 24
Total Noncurrent Liabilities		 35 94 183 127 675 163
Capital Lease Obligations		 35 41 40 29 33 14
Noncurrent Deferred & Payable Income Tax Liabilities		 0.23 - - - - 1.82
Other Noncurrent Operating Liabilities		 0.00 53 143 98 642 75
Total Equity & Noncontrolling Interests		 721 572 570 779 869 -48
Total Preferred & Common Equity		 721 572 570 779 869 -48
Total Common Equity		 721 572 570 779 869 -48
Common Stock		 28 30 25 25 26 13
Retained Earnings		 -1,453 -1,732 -1,397 -1,196 -788 -579
Accumulated Other Comprehensive Income / (Loss)		 0.04 -0.07 -0.15 -0.04 0.07 0.02
Other Equity Adjustments		 2,146 2,274 1,944 1,956 1,630 518

Quarterly Balance Sheets for CureVac

No quarterly balance sheets for CureVac are available.

Annual Metrics And Ratios for CureVac

This table displays calculated financial ratios and metrics derived from CureVac's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 555.77% -24.70% -86.31% 831.90% 242.92% 81.59% 0.00%
EBITDA Growth		 175.50% -8.53% 46.31% -208.49% -39.55% -32.02% 0.00%
EBIT Growth		 168.71% -7.89% 42.91% -194.32% -41.17% -34.82% 0.00%
NOPAT Growth		 183.40% -7.89% 42.91% -194.32% -41.17% -34.82% 0.00%
Net Income Growth		 158.33% -8.03% 42.83% -195.42% -40.73% -37.47% 0.00%
EPS Growth		 157.10% 10.61% 40.27% -125.51% 4.85% 0.00% 0.00%
Operating Cash Flow Growth		 135.58% 3.21% 63.10% -230.02% 17,145.78% 95.59% 0.00%
Free Cash Flow Firm Growth		 127.68% 23.98% 59.36% -252.53% 850.11% 0.00% 0.00%
Invested Capital Growth		 53.15% 114.01% 164.80% 83.87% -29,144.36% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 74.90% -60.99% -72.80% 66.93% 50.93% -25.84% -37.86%
EBITDA Margin		 34.20% -297.07% -206.12% -52.54% -158.71% -390.00% -536.42%
Operating Margin		 34.20% -326.43% -227.83% -54.61% -172.92% -420.06% -565.80%
EBIT Margin		 34.20% -326.43% -227.83% -54.61% -172.92% -420.06% -565.80%
Profit (Net Income) Margin		 29.06% -326.68% -227.71% -54.51% -171.95% -419.00% -553.50%
Tax Burden Percent		 84.97% 100.08% 99.95% 99.81% 99.44% 99.75% 100.15%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.68%
Effective Tax Rate		 15.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 80.66% -171.03% 0.00% 0.00% 0.00% -6,371.59% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 80.66% -151.96% 0.00% 0.00% 0.00% -6,503.97% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -54.69% 120.64% 0.00% 0.00% 0.00% 6,838.27% 0.00%
Return on Equity (ROE)		 25.97% -50.39% -39.48% -56.54% -38.43% 466.67% 0.00%
Cash Return on Invested Capital (CROIC)		 38.67% -243.65% -503.20% 0.00% 0.00% -6,571.59% 0.00%
Operating Return on Assets (OROA)		 23.20% -32.09% -23.89% -29.57% -15.92% -76.65% 0.00%
Return on Assets (ROA)		 19.72% -32.11% -23.88% -29.52% -15.83% -76.46% 0.00%
Return on Common Equity (ROCE)		 25.97% -50.39% -39.48% -56.54% -38.43% 466.67% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 23.28% -50.33% -46.70% -59.80% -18.15% 233.34% 0.00%
Net Operating Profit after Tax (NOPAT)		 168 -201 -187 -327 -111 -79 -58
NOPAT Margin		 29.06% -228.50% -159.48% -38.23% -121.04% -294.04% -396.06%
Net Nonoperating Expense Percent (NNEP)		 0.00% -19.07% -11.48% -11.22% -6.08% 132.37% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 22.21% - - - - - -
Cost of Revenue to Revenue		 25.10% 160.99% 172.80% 33.07% 49.07% 125.84% 137.86%
SG&A Expenses to Revenue		 13.28% 120.13% 97.84% 13.52% 72.29% 212.80% 196.48%
R&D to Revenue		 27.42% 145.31% 57.20% 108.02% 151.56% 181.41% 324.16%
Operating Expenses to Revenue		 40.70% 265.44% 155.03% 121.55% 223.86% 394.22% 529.07%
Earnings before Interest and Taxes (EBIT)		 198 -288 -267 -467 -159 -112 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 198 -262 -241 -449 -146 -104 -79
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 1.06 1.44 1.98 7.95 1.24 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.10 1.52 2.10 8.10 1.27 0.00 0.00
Price to Revenue (P/Rev)		 1.32 9.32 9.64 7.24 11.78 7.98 14.48
Price to Earnings (P/E)		 4.55 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 21.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.19 2.59 8.51 0.00 0.00 107.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.52 4.73 5.45 6.20 0.00 9.92 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 1.52 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 1.52 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 1.79 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 2.85 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 3.73 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.05 0.07 0.07 0.04 0.04 -1.80 0.00
Long-Term Debt to Equity		 0.05 0.07 0.07 0.04 0.04 -1.80 0.00
Financial Leverage		 -0.68 -0.79 -1.03 -1.51 -1.87 -1.05 0.00
Leverage Ratio		 1.32 1.57 1.65 1.92 2.43 -3.05 0.00
Compound Leverage Factor		 1.32 1.57 1.65 1.92 2.43 -3.05 0.00
Debt to Total Capital		 4.61% 6.65% 6.51% 3.56% 3.64% 224.63% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.61% 6.65% 6.51% 3.56% 3.64% 224.63% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.39% 93.35% 93.49% 96.44% 96.36% -124.63% 0.00%
Debt to EBITDA		 0.18 -0.16 -0.16 -0.06 -0.23 -0.83 0.00
Net Debt to EBITDA		 -2.35 1.55 2.03 1.98 10.87 -0.50 0.00
Long-Term Debt to EBITDA		 0.18 -0.16 -0.16 -0.06 -0.23 -0.83 0.00
Debt to NOPAT		 0.21 -0.20 -0.21 -0.09 -0.30 -1.10 0.00
Net Debt to NOPAT		 -2.76 2.01 2.63 2.72 14.26 -0.66 0.00
Long-Term Debt to NOPAT		 0.21 -0.20 -0.21 -0.09 -0.30 -1.10 0.00
Altman Z-Score		 3.88 -1.68 -0.42 5.79 0.74 -6.95 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 7.28 2.57 3.74 2.63 5.61 2.04 0.00
Quick Ratio		 6.85 2.24 3.23 2.32 5.35 1.70 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 80 -287 -377 -928 609 -81 0.00
Operating Cash Flow to CapEx		 552.22% -485.30% -306.98% -573.20% 1,103.23% 0.00% -503.36%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -269.49
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -323.03
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.68 0.10 0.10 0.54 0.09 0.18 0.00
Accounts Receivable Turnover		 37.98 7.80 8.45 77.08 9.73 1.52 0.00
Inventory Turnover		 9.45 4.41 4.03 6.95 3.64 4.84 0.00
Fixed Asset Turnover		 2.44 0.37 0.58 6.29 1.36 0.50 0.00
Accounts Payable Turnover		 4.08 2.15 1.81 3.31 2.67 4.63 0.00
Days Sales Outstanding (DSO)		 9.61 46.78 43.17 4.74 37.50 240.26 0.00
Days Inventory Outstanding (DIO)		 38.61 82.73 90.66 52.50 100.18 75.41 0.00
Days Payable Outstanding (DPO)		 89.38 169.50 201.43 110.42 136.88 78.79 0.00
Cash Conversion Cycle (CCC)		 -41.17 -39.98 -67.60 -53.19 0.80 236.88 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 252 160 75 -116 -717 2.47 0.00
Invested Capital Turnover		 2.78 0.75 -5.75 -2.05 -0.26 21.67 0.00
Increase / (Decrease) in Invested Capital		 87 85 191 601 -720 2.47 0.00
Enterprise Value (EV)		 300 416 638 5,302 -502 265 0.00
Market Capitalization		 764 821 1,128 6,192 1,081 213 213
Book Value per Share		 $3.22 $2.93 $3.05 $4.32 $4.64 ($3.60) $0.00
Tangible Book Value per Share		 $3.10 $2.77 $2.87 $4.23 $4.55 ($4.08) $0.00
Total Capital		 756 613 610 808 902 39 0.00
Total Debt		 35 41 40 29 33 87 0.00
Total Long-Term Debt		 35 41 40 29 33 87 0.00
Net Debt		 -464 -404 -491 -890 -1,583 52 0.00
Capital Expenditures (CapEx)		 19 61 100 145 58 -43 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -122 -73 -259 -220 -1.79 0.00
Debt-free Net Working Capital (DFNWC)		 470 323 458 659 1,395 33 0.00
Net Working Capital (NWC)		 470 323 458 659 1,395 33 0.00
Net Nonoperating Expense (NNE)		 0.00 86 80 139 47 33 23
Net Nonoperating Obligations (NNO)		 -469 -411 -496 -895 -1,586 51 0.00
Total Depreciation and Amortization (D&A)		 0.00 26 25 18 13 8.04 4.33
Debt-free, Cash-free Net Working Capital to Revenue		 -4.96% -138.70% -62.17% -30.34% -240.19% -6.69% 0.00%
Debt-free Net Working Capital to Revenue		 81.36% 366.64% 391.19% 77.09% 1,521.13% 122.04% 0.00%
Net Working Capital to Revenue		 81.36% 366.64% 391.19% 77.09% 1,521.13% 122.04% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.75 ($1.18) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 224.34M 223.99M 0.00 0.00 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 $0.75 ($1.18) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 224.34M 223.99M 0.00 0.00 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 224.34M 223.99M 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 168 -201 -187 -327 -111 -79 -58
Normalized NOPAT Margin		 29.06% -228.50% -159.48% -38.23% -121.04% -294.04% -396.06%
Pre Tax Income Margin		 34.20% -326.43% -227.83% -54.61% -172.92% -420.06% -552.65%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -264.81
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -185.37
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -318.35
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -238.91
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CureVac

No quarterly metrics and ratios for CureVac are available.

Frequently Asked Questions About CureVac's Financials

When does CureVac's financial year end?

According to the most recent income statement we have on file, CureVac's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CureVac's net income changed over the last 6 years?

CureVac's net income appears to be on a downward trend, with a most recent value of $167.88 million in 2024, falling from -$81.54 million in 2018. The previous period was -$287.80 million in 2023. See where experts think CureVac is headed by visiting CureVac's forecast page.

What is CureVac's operating income?
CureVac's total operating income in 2024 was $197.58 million, based on the following breakdown:
  • Total Gross Profit: $432.73 million
  • Total Operating Expenses: $235.14 million
How has CureVac revenue changed over the last 6 years?

Over the last 6 years, CureVac's total revenue changed from $14.73 million in 2018 to $577.72 million in 2024, a change of 3,821.8%.

How much debt does CureVac have?

CureVac's total liabilities were at $109.95 million at the end of 2024, a 63.4% decrease from 2023, and a 43.5% decrease since 2019.

How much cash does CureVac have?

In the past 5 years, CureVac's cash and equivalents has ranged from $34.44 million in 2019 to $1.62 billion in 2020, and is currently $498.66 million as of their latest financial filing in 2024.

How has CureVac's book value per share changed over the last 6 years?

Over the last 6 years, CureVac's book value per share changed from 0.00 in 2018 to 3.22 in 2024, a change of 321.9%.


Related Companies

This page (NASDAQ:CVAC) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored